Advaxis, Inc.(NASDAQ:ADXS) Receives Notice of Allowance


Advaxis, Inc.(NASDAQ:ADXS), a clinical development-stage company, said Monday that it has received notice of allowance from the United States Patent and Trademark Office (USPTO) on two patents covering the composition and methods of use for ADXS-cHER2. 

The company is developing ADXS-cHER2 to target the Her2 receptor, which is overexpressed in certain solid-tumor cancers, including bone cancer (or osteosarcoma), breast cancer, esophageal, and gastric cancer. ADXS also plans to initiate a Phase 1 trial with ADXS-cHER2 in pediatric osteosarcoma, for which it received Orphan Drug Designation, and is pursuing early development clinical collaborations for breast, esophageal and gastric cancers. 

The first patent – Patent Number 12/945,386 – covers composition for ADXS-cHER2, as well as methods of composition use for preventing or eliciting an immune response against, or treating, tumors that express Her2/neu in humans. This patent also covers ADXS-cHER2 use within the tumor, specifically: increasing the ratio of CD8 T cells to regulatory T cells (Tregs) and decreasing the frequency of Tregs and myeloid-derived suppressor cells (MDSCs). Additionally, the patent covers ADXS-cHER2 use for preventing an escape mutation in the treatment of Her2/neu over-expressing tumors in a subject. 

The second patent – Patent Number 13/210,696 – covers methods of ADXS-cHER2 use for preventing, eliciting an immune response against, or treating Her-2/neu-expressing tumors, such as osteosarcoma, in non-human animals, particularly pet dogs. The allowed method claims also cover ADXS-cHER2 use for preventing an escape mutation in the treatment of Her2/neu over-expressing tumors in non-human animals, particularly dogs. 

Shares closed at 3.07 with a 52-week range of $2.46 – $11.70. 

Get Free Updates and Stock Alerts!

*We only send one email per week

Get Winning Stock Alerts!

Our track record speaks for itself! Our last 7 alerts have delivered combined gains in excess of 300% and there are no signs of slowing down. Join now before you miss out on our next big runner!

We will never sell or share your information.